Hedge Funds Go Bottom Fishing in Biopharma

Over the past few weeks, four different life sciences hedge funds have taken stakes of at least 5 percent in more than a half dozen stocks.

Carsten Snejbjerg/Bloomberg

Carsten Snejbjerg/Bloomberg

Is it time to buy?

That’s the number-one question facing investors as the stock indices sink ever deeper into bear market territory.

One group of investors who have been aggressively making big bets, however, are the managers who specialize in biopharma and life sciences stocks.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.